AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer
published in: Clinical Cancer Research
date of publication: 2010-02-09
language: English
main subject: sapitinib, Erb-b2 receptor tyrosine kinase 2
Cites articles
There is nothing here
Article - wd:Q39741482